Polaryx Therapeutics, Inc. (PLYX) SEC Filings

Polaryx Therapeutics, Inc. (PLYX) reported the appointment of Will Charlton, M.D., M.A.S. as Chief Medical Officer, effective September 1, 2026. Dr. Charlton is a board-certified pediatric endocrinologist with over 15 years of rare disease and pediatric drug development experience, including senior roles at Tyra Biosciences, Spruce Biosciences, 89bio, Ascendis Pharma, and Allergan.

The company highlighted his role in leading Phase 2 rare disease programs and redesigning clinical strategies for pediatric indications. Polaryx reiterated plans to initiate SOTERIA, a Phase 2 open-label, single-arm trial of PLX-200 in multiple lysosomal storage disorders, in the fourth quarter of 2026, initially at sites in the United States and then other jurisdictions.

Polaryx Therapeutics, Inc. is a clinical-stage biotech focused on therapies for rare pediatric lysosomal storage disorders and reported continued operating losses for the quarter ended June 30, 2026. Net loss was $1.4 million for the quarter and $3.9 million for the first six months, compared with $1.0 million and $6.1 million in the prior-year periods.

Cash and cash equivalents increased to $11.5 million from $5.1 million at year-end 2025, driven by a $10.0 million May 2026 equity financing that issued 2,502,696 shares. Total assets were $11.8 million, with minimal liabilities of $0.9 million and stockholders’ equity of $10.9 million.

The company plans a Phase 2 proof-of-concept basket trial, SOTERIA, for PLX‑200 across CLN2, CLN3, Krabbe disease and Sandhoff disease, with initiation expected in the second half of 2026 and expanded enrollment to 24 participants. Management projects existing cash will fund operations through the first quarter of 2027, but recurring losses and dependence on external financing raise substantial doubt about its ability to continue as a going concern.

Polaryx Therapeutics, Inc. is holding a virtual 2026 annual stockholders’ meeting on September 10, 2026 at 9:00 a.m. Eastern Time. Stockholders of record at the close of business on July 27, 2026, when 49,845,993 common shares were outstanding, may vote.

Stockholders are asked to elect two Class I directors, Alex Yang and Mitchel Berger, to terms ending at the 2029 meeting, and to ratify Grant Thornton LLP as independent registered public accounting firm for 2026. The board is classified into three staggered classes, and has determined that three directors are independent under Nasdaq rules. A major holder affiliated with Mstone controls 22,833,249 shares, or 45.81% of voting power. The proxy also details executive compensation built largely around restricted stock units, a new 2025 equity incentive plan with share reserves, and several related-party arrangements, including service and licensing agreements with Mstone and Rush University Medical Center.

Polaryx Therapeutics, Inc. reported that its Chief Medical Officer, Lisa Bollinger, MD, resigned from her position effective immediately on July 19, 2026. The company states it does not anticipate this departure will affect its previously disclosed clinical timelines, regulatory plans or development strategy. A search for a successor has begun, and in the meantime, existing members of the leadership team will assume the responsibilities previously overseen by Dr. Bollinger.

Polaryx Therapeutics, Inc. determined that its 2026 Annual Meeting of Stockholders will be held virtually on September 10, 2026. Stockholders of record of the company’s common stock at the close of business on July 27, 2026 will be entitled to notice of and to vote at the meeting, subject to the company’s reserved right to change the record date, meeting date, or location.

Because no annual meeting was held in 2025, stockholder proposals and director nominations intended for inclusion in the proxy materials under Rule 14a-8 must be received by the company, attention Alex Yang at its Paramus, New Jersey address, by the close of business on July 27, 2026 and must comply with SEC rules, Nevada law and the company’s Amended and Restated Bylaws. Proposals or nominations received after that date will be considered untimely and will not be included or considered at the meeting.

Polaryx Therapeutics, Inc. reported an insider-related open-market purchase of common stock. On May 27, 2026, MStone Partners Healthcare Limited bought 88,453 shares of Polaryx common stock at $4.07 per share, in a private placement that generated $360,000 in gross proceeds for the company. After this transaction, MStone held 24,233,249 shares of common stock indirectly. Polaryx CEO Alex Keun Mo Yang is the founder and Chief Executive Officer of MStone and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.

Polaryx Therapeutics, Inc. entered into a private placement, selling 2,502,696 common shares for aggregate gross proceeds of $10 million, representing about 5.3% of its outstanding shares immediately before the transaction. The weighted average price was approximately $4.00 per share.

The company plans to use the net proceeds, together with existing cash, to fund its Phase 2 SOTERIA basket trial of PLX-200 across multiple lysosomal storage disorders, continue research and development, and for working capital and general corporate purposes. Management states this financing is expected to extend Polaryx’s operating runway through the second quarter of 2027 and support the planned launch of SOTERIA in the second half of 2026.

Polaryx Therapeutics, Inc. reported a net loss of approximately $2.5 million for the quarter ended March 31, 2026, narrower than the $5.1 million loss a year earlier. Operating expenses fell sharply as research and development declined to $679 thousand, mainly because a one-time, stock-based gene therapy license charge in 2025 did not recur.

General and administrative costs rose to $1.3 million, reflecting new public-company expenses and higher stock-based compensation to an advisor. Cash and cash equivalents were $3.1 million, with $2.1 million used in operating activities in the quarter and working capital of about $2.5 million as of March 31, 2026.

Polaryx remains a clinical-stage company with no product revenue and an accumulated deficit of roughly $102.2 million. Management discloses substantial doubt about its ability to continue as a going concern and expects existing cash to fund operations only through the third quarter of 2026, while it advances its PLX‑200 lysosomal storage disorder program toward a planned Phase 2 basket trial.